Usability, Face Validity, Feasibility, and Reliability of 3 Neurocritical Care Electronic Clinical Quality Measures.

IF 2.3 Q3 CLINICAL NEUROLOGY
Neurology. Clinical practice Pub Date : 2025-08-01 Epub Date: 2025-07-02 DOI:10.1212/CPJ.0000000000200497
Abhijit Vijay Lele, Emma Pendl-Robinson, Samuel Simon, Keith Dombrowski, Bradley J Kolls, Matthew W Luedke, Christine T Fong, Erin Lee, Paul M Vespa, Sarah Livesay, Keri Calkins, Dmitriy Poznyak
{"title":"Usability, Face Validity, Feasibility, and Reliability of 3 Neurocritical Care Electronic Clinical Quality Measures.","authors":"Abhijit Vijay Lele, Emma Pendl-Robinson, Samuel Simon, Keith Dombrowski, Bradley J Kolls, Matthew W Luedke, Christine T Fong, Erin Lee, Paul M Vespa, Sarah Livesay, Keri Calkins, Dmitriy Poznyak","doi":"10.1212/CPJ.0000000000200497","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>The field of neurology lacks neurocritical care (NCC) quality measures because of the complexity of neurologic disorders and challenges in data collection, hindering efforts to assess care quality and improve patient outcomes. This study examined the feasibility, usability, and scientific acceptability of 3 new facility-level neurology electronic clinical quality measures (eCQMs): (1) adult patients with generalized convulsive status epilepticus (GCSE) treated with benzodiazepine within 20 minutes of arrival to the emergency department, (2) dexamethasone administration before or within an hour of the first dose of antibiotics in patients with acute bacterial meningitis (BM), and (3) immunomodulatory therapy [plasma exchange or IV immunoglobulin] for myasthenic crisis (MG).</p><p><strong>Methods: </strong>We evaluated the feasibility, usability, face validity, and reliability of the 3 eCQMs across 3 sites in the United States using a combination of qualitative and quantitative methodologies. The feasibility of reporting was evaluated by the percentage of data elements that do not require manual patient record review. Face validity was determined through semistructured clinician interviews and web survey, and usability was assessed through clinician interviews. Signal-to-noise reliability was calculated based on the testing data obtained from 3 hospitals.</p><p><strong>Results: </strong>The total number of denominator-eligible patients in the sample was 86 (GCSE), 88 (BM), and 193 (MG). The mean measure rates were as follows: GCSE, 12.3% (11.3%-13.3%); BM, 23.3% (10.8%-35.7%); and MG, 64.2% (46.2%-81.4%). All 3 eCQMs had high face validity (GCSE: 90%, BM: 90%, MG: 94%). The measures had high reliability: GCSE, 0.890 (0.816-0.963); BM, 0.817 (0.669-0.964); and MG, 0.958 (0.948-0.969). We found high feasibility for MG; however, BM and GCSE had feasibility concerns for several key data elements. Clinicians supported the measures' potential to improve care but expressed several usability concerns.</p><p><strong>Discussion: </strong>The eCQMs showed potential for being used for quality improvement. However, significant barriers to feasibility include inconsistent recording of diagnosis and procedure codes in electronic health records and underestimation of denominator and/or numerator cases, which hinder reporting in Centers for Medicare & Medicaid Services quality improvement programs. Continued refinement of the eCQM specifications is required before they can be implemented to enhance their impact on NCC quality.</p>","PeriodicalId":19136,"journal":{"name":"Neurology. Clinical practice","volume":"15 4","pages":"e200497"},"PeriodicalIF":2.3000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240562/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology. Clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1212/CPJ.0000000000200497","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objectives: The field of neurology lacks neurocritical care (NCC) quality measures because of the complexity of neurologic disorders and challenges in data collection, hindering efforts to assess care quality and improve patient outcomes. This study examined the feasibility, usability, and scientific acceptability of 3 new facility-level neurology electronic clinical quality measures (eCQMs): (1) adult patients with generalized convulsive status epilepticus (GCSE) treated with benzodiazepine within 20 minutes of arrival to the emergency department, (2) dexamethasone administration before or within an hour of the first dose of antibiotics in patients with acute bacterial meningitis (BM), and (3) immunomodulatory therapy [plasma exchange or IV immunoglobulin] for myasthenic crisis (MG).

Methods: We evaluated the feasibility, usability, face validity, and reliability of the 3 eCQMs across 3 sites in the United States using a combination of qualitative and quantitative methodologies. The feasibility of reporting was evaluated by the percentage of data elements that do not require manual patient record review. Face validity was determined through semistructured clinician interviews and web survey, and usability was assessed through clinician interviews. Signal-to-noise reliability was calculated based on the testing data obtained from 3 hospitals.

Results: The total number of denominator-eligible patients in the sample was 86 (GCSE), 88 (BM), and 193 (MG). The mean measure rates were as follows: GCSE, 12.3% (11.3%-13.3%); BM, 23.3% (10.8%-35.7%); and MG, 64.2% (46.2%-81.4%). All 3 eCQMs had high face validity (GCSE: 90%, BM: 90%, MG: 94%). The measures had high reliability: GCSE, 0.890 (0.816-0.963); BM, 0.817 (0.669-0.964); and MG, 0.958 (0.948-0.969). We found high feasibility for MG; however, BM and GCSE had feasibility concerns for several key data elements. Clinicians supported the measures' potential to improve care but expressed several usability concerns.

Discussion: The eCQMs showed potential for being used for quality improvement. However, significant barriers to feasibility include inconsistent recording of diagnosis and procedure codes in electronic health records and underestimation of denominator and/or numerator cases, which hinder reporting in Centers for Medicare & Medicaid Services quality improvement programs. Continued refinement of the eCQM specifications is required before they can be implemented to enhance their impact on NCC quality.

3种神经危重症电子临床质量测量的可用性、面效度、可行性和可靠性。
背景和目的:由于神经系统疾病的复杂性和数据收集方面的挑战,神经病学领域缺乏神经危重症护理(NCC)质量测量,阻碍了评估护理质量和改善患者预后的努力。本研究考察了3种新的设施级神经病学电子临床质量测量(eCQMs)的可行性、可用性和科学可接受性:(1)全身性惊厥性癫痫持续状态(GCSE)的成人患者在到达急诊科20分钟内给予苯二氮平;(2)急性细菌性脑膜炎(BM)患者在首次给药前或1小时内给予地塞米松;(3)肌无力危象(MG)的免疫调节治疗[血浆置换或静脉注射免疫球蛋白]。方法:采用定性和定量相结合的方法,对美国3个地点的3个ecqm的可行性、可用性、面部效度和可靠性进行了评估。报告的可行性通过不需要手动患者记录审查的数据元素的百分比来评估。通过半结构化临床医生访谈和网络调查来确定面部效度,通过临床医生访谈来评估可用性。根据3家医院的检测数据计算信噪比信度。结果:样本中符合分母条件的患者总数为86例(GCSE), 88例(BM)和193例(MG)。平均测量率为:普通中等教育,12.3% (11.3% ~ 13.3%);Bm, 23.3% (10.8% ~ 35.7%);MG占64.2%(46.2% ~ 81.4%)。3种ecqm均具有较高的面效度(GCSE: 90%, BM: 90%, MG: 94%)。测量结果具有高信度:GCSE为0.890 (0.816-0.963);Bm, 0.817 (0.669-0.964);MG为0.958(0.948 ~ 0.969)。我们发现MG具有很高的可行性;但是,BM和GCSE对几个关键数据要素存在可行性问题。临床医生支持这些措施改善护理的潜力,但表达了一些可用性方面的担忧。讨论:ecqm显示了用于质量改进的潜力。然而,可行性的重大障碍包括电子健康记录中诊断和程序代码的不一致记录以及分母和/或分子病例的低估,这阻碍了医疗保险和医疗补助服务中心质量改进计划的报告。在实施eCQM规范以增强其对NCC质量的影响之前,需要持续改进eCQM规范。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Neurology. Clinical practice
Neurology. Clinical practice CLINICAL NEUROLOGY-
CiteScore
4.00
自引率
0.00%
发文量
77
期刊介绍: Neurology® Genetics is an online open access journal publishing peer-reviewed reports in the field of neurogenetics. The journal publishes original articles in all areas of neurogenetics including rare and common genetic variations, genotype-phenotype correlations, outlier phenotypes as a result of mutations in known disease genes, and genetic variations with a putative link to diseases. Articles include studies reporting on genetic disease risk, pharmacogenomics, and results of gene-based clinical trials (viral, ASO, etc.). Genetically engineered model systems are not a primary focus of Neurology® Genetics, but studies using model systems for treatment trials, including well-powered studies reporting negative results, are welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信